Current issues in contraception

Mayo Clinic Proceedings

Volumn 88, Issue 3, 2013, Pages 295-299

  Marnach, Mary L ^a   Long, Margaret E ^a   Casey, Petra M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CONTRACEPTIVE AGENT; DESOGESTREL; DOXYCYCLINE; DROSPIRENONE; ESCITALOPRAM; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; ETHINYLESTRADIOL; ETONOGESTREL; GESTAGEN; GESTODENE; LEVONORGESTREL; LONG ACTING DRUG; MEDROXYPROGESTERONE ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; NORGESTIMATE;

ABDOMINAL CRAMP; AMENORRHEA; ARTERY THROMBOSIS; BRAIN ISCHEMIA; CANCER RISK; CLINICAL PRACTICE; COMORBIDITY; CONFERENCE PAPER; CONTRACEPTION; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LIFESTYLE; MENORRHAGIA; METRORRHAGIA; MIGRAINE; OBESITY; PATIENT COMPLIANCE; QT PROLONGATION; TORSADE DES POINTES; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; UTERINE CERVIX CANCER; UTERUS BLEEDING; VENOUS THROMBOEMBOLISM;

EID: 84876571451     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.01.007     Document Type: Conference Paper

References (25)

1. Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception. 2011; 84(5):478-485.
2. Centers for Disease Control and Prevention. U.S. medical eligibility criteria for contraceptive use, 2010: adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th ed [early release]. Morb Mortal Wkly Rep. 2010;59:1-88. Centers for Disease Control and Prevention website, http://www.cdc.gov/mmwr/pdf/rr/rr59e0528.pdf. Accessed December 28, 2012.
3. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 121: Long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2011;118(1): 184-196.
4. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception. 2006;74(2): 100-103. (Pubitemid 44062466)
5. Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol. 2011;117(4):777-787.
6. ACOG Practice Bulletin No. 110: Noncontraceptive uses of hormonal contraceptives. Obstet Gynecol. 2010;115(1):206-218.
7. Vieweg WV, Hasnain M, Howland RH, et al. Citalopram, QTc interval prolongation, and torsade de pointes: how should we apply the recent FDA ruling?Am J Med. 2012;125(9):859-868.
8. Sheeler RD, Ackerman MJ, Richelson E, et al. Considerations on safety concerns about citalopram prescribing. Mayo Clin Proc. 2012;87(11):1042-1045.
9. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890.
10. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011;342:d2151.
11. US Food and Drug Administration. Background Document for Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee. NDA 21-180 Ortho Evra. http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeeting Materials/Drugs/ ReproductiveHealthDrugsAdvisoryCommittee/UCM282634.pdf. Published December 9, 2011. Accessed December 28, 2012.
12. US Food and Drug Administration. Birth control pills containing drospirenone: label changedproducts may be associated with higher risk for blood clots. US Food and Drug Administration website. http://www.fda.gov/Safety/ MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm299605.htm. Updated April 10, 2012. Accessed December 28, 2012.
13. Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestogens alone [letter]. Lancet. 1999;354(9190):1610-1611. (Pubitemid 29515957)
14. Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366(24):2257-2266.
15. Shuster LT, Faubion SS, Sood R, Casey PM. Hormonal manipulation strategies in the management of menstrual migraine and other hormonally related headaches. Curr Neurol Neurosci Rep. 2011;11(2):131-138.
16. Faubion SS, Casey PM, Shuster LT. Hormonal contraception and migraine: clinical considerations. Curr Pain Headache Rep. 2012;16(5):461-466.
17. Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol. 2012;120(1): 21-26.
18. Glasier A, Cameron ST, Blithe D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? data from randomized trials of ulipristal acetate and levonorgestrel. Contraception. 2011;84(4):363-367.
19. Peipert JF, Madden T, Allsworth JE, Secura GM. Preventing unintended pregnancies by providing no-cost contraception. Obstet Gynecol. 2012;120(6):1291-1297.
20. Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists. Committee opinion no. 539: Adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2012;120(4):983-988.
21. Castellsagué X, Diaz M, Vaccarella S, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol. 2011;12(11):1023-1031.
22. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370(9599):1609-1621.
23. Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care. 2008;13(suppl 1):13-28. (Pubitemid 351364453)
24. Casey PM, Long ME, Marnach ML, Bury JE. Bleeding related to etonogestrel subdermal implant in a US population. Contraception. 2011;83(5):426-430.
25. Weisberg E, Hickey M, Palmer D, et al. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod. 2009;24(8):1852-1861.